Last reviewed · How we verify

Zhang Xiaofeng,MD — Portfolio Competitive Intelligence Brief

Zhang Xiaofeng,MD pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Tegoprazan 50 mg, tablets, orally, bid Tegoprazan 50 mg, tablets, orally, bid marketed
Tegoprazan 50 mg, tablets, orally, qd Tegoprazan 50 mg, tablets, orally, qd marketed Potassium-competitive acid blocker (P-CAB) H+/K+-ATPase Gastroenterology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Aga Khan University · 1 shared drug class
  2. Ain Shams University · 1 shared drug class
  3. Cinclus Pharma Holding AB · 1 shared drug class
  4. Daewoong Pharmaceutical Co. LTD. · 1 shared drug class
  5. Humanis Saglık Anonim Sirketi · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Zhang Xiaofeng,MD:

Cite this brief

Drug Landscape (2026). Zhang Xiaofeng,MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zhang-xiaofeng-md. Accessed 2026-05-16.

Related